VEGFA and neuroblastoma: Indeed, selective binding of bevacizumab to VEGF proteins coupled with SiO2-layered dihydroxane DOX-loaded nanocomposites for NB treatment significantly improved DOX cellular uptake and targeting delivery efficiency, inhibited tumor cell angiogenesis, reduced side effects of DOX, and inhibited VEGF-mediated angiogenesis and tumorigenesis (Zhu et al., 2017).